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ABSTRACT
Objective To examine the hypothesis that risk of
oesophageal, but not of gastric or colorectal, cancer is
increased in users of oral bisphosphonates.
DesignNestedcase-controlanalysiswithinaprimarycare
cohort of about 6 million people in the UK, with
prospectively recorded information on prescribing of
bisphosphonates.
Setting UK General Practice Research Database cohort.
Participants Men and women aged 40 years or over—
2954 with oesophageal cancer, 2018 with gastric cancer,
and 10641 with colorectal cancer, diagnosed in 1995-
2005;fivecontrolspercasematchedforage,sex,general
practice, and observation time.
Main outcome measures Relative risks for incident
invasive cancers of the oesophagus, stomach, and
colorectum, adjusted for smoking, alcohol, and body
mass index.
Results The incidence of oesophageal cancer was
increased in people with one or more previous
prescriptions for oral bisphosphonates compared with
those with no such prescriptions (relative risk 1.30, 95%
confidence interval 1.02 to1.66; P=0.02). Risk of
oesophageal cancer was significantly higher for 10 or
more prescriptions (1.93, 1.37 to 2.70) than for one to
nine prescriptions (0.93, 0.66 to 1.31) (P for
heterogeneity=0.002), and for use for over 3 years (on
average, about 5 years: relative risk v no prescription,
2.24, 1.47 to 3.43). Risk of oesophageal cancer did not
differ significantly by bisphosphonate type, and risk in
those with 10 or more bisphosphonate prescriptions did
not vary by age, sex, smoking, alcohol intake, or body
mass index; by diagnosis of osteoporosis, fracture, or
upper gastrointestinal disease; or by prescription of acid
suppressants, non-steroidal anti-inflammatory drugs, or
corticosteroids. Cancers of the stomach and colorectum
werenotassociatedwithprescriptionofbisphosphonate:
relativerisksforoneormoreversusnoprescriptionswere
0.87(0.64to1.19)and0.87(0.77to1.00).Thespecificity
of the association for oesophageal cancer argues against
methodological problems in the selection of cases and
controls or in the analysis.
Conclusions The risk of oesophageal cancer increased
with 10 or more prescriptions for oral bisphosphonates
and with prescriptions over about a five year period. In
Europe and North America, the incidence of oesophageal
cancer at age 60-79 is typically 1 per 1000 population
over five years, and this is estimated to increase to about
2 per 1000 with five years’ use of oral bisphosphonates.
INTRODUCTION
Adverse gastrointestinal effects are common among
people who take oral bisphosphonates for the preven-
tion and treatment of osteoporosis; they range from
dyspepsia, nausea, and abdominal pain to erosive
oesophagitis and oesophageal ulcers.
1 Recent case
reports have suggested a possible increase in the risk
ofoesophagealcancerwithuseofsuchbisphosphonate
preparations.
2 We report here on the relation between
prospectively recorded prescribing information for
oral bisphosphonates and the subsequent incidence
of cancers of the oesophagus, stomach, and colo-
rectum, using data from the UK General Practice
Research Database cohort.
METHODS
The General Practice Research Database is a compu-
terised database containing anonymised patient
records for about 6 million people in the United King-
domregisteredwithaNationalHealthServiceprimary
care physician (general practitioner).
3 Every prescrip-
tionissuedbythegeneralpractitioner,allconsultations
withthegeneralpractitioner,testresultsanddiagnoses
from primary and secondary care, referrals to outpati-
ent clinics, hospital admissions, and deaths are coded
by the general practitioner and entered into the data-
base, as are basic demographic data and certain life-
style data. General Practice Research Database
prescriptiondatahavebeenshowntobevirtuallycom-
plete, and the data on incidence of cancer (based on
hospital records) are around 95% valid and
complete.
45Individual patients are recorded as enter-
ingtheGeneralPracticeResearchDatabasewhenthey
are registered with a participating general practice and
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ing general practice, leave the NHS (for example,
throughemigration),ordie.Thedatabasethusconsists
of longitudinal medical records in which patients’
length of follow-up is the time between entering and
leaving the database.
We did a nested case-control study of gastro-
intestinal cancer in the General Practice Research
Database. We defined cases as men and women aged
at least 40 years with a diagnosis of incident invasive
canceroftheoesophagus(ICD-10codeC15),stomach
(C16),orcolorectum(C18-20)recordedbetween1995
and 2005 and with at least 12 months of follow-up
within the General Practice Research Database before
the date of diagnosis. For each case, we selected five
controls with no record of gastrointestinal cancer
before the index date (defined as the date of diagnosis
of the case) matched on age at index date (to within
2 years), sex, participating general practice, and obser-
vation period in the database. The observation period
for this study was, for both cases and their matched
controls, the period between the date of entry of the
case into the General Practice Research Database and
the date of diagnosis (that is, patients were eligible as
controls only if their follow-up time in the database
included the observation period of their matched
case,andfortheanalyseswesettheobservationperiod
of the controls to match that of the cases exactly). We
defined patients as exposed to bisphosphonates if they
had a record within the observation period of at least
one prescription for any oral bisphosphonate prepara-
tion that is licensed in the UK for use in osteoporosis
(British National Formulary section 6.6.2). We excluded
patients with prescriptions for bisphosphonates
licensed to treat Paget’s disease or bone metastases.
We estimated duration of use of bisphosphonates as
the time between the first prescription and last pre-
scription within the observation period.
We used conditional logistic regression to calculate
relative risks and 95% confidence intervals for oeso-
phageal, stomach, and colorectal cancer in relation to
prescription of oral bisphosphonates. We used the
Statacomputingpackage(release10.1)forallanalyses.
We adjusted the main analyses for smoking status (lat-
estrecordbeforeindexdate:never,past,current,miss-
ing), alcohol intake (latest record before index date:
non-drinker, drinker, missing), and body mass index
(latest record at least two years before index date:
<25, 25-30, ≥30, missing). We assigned missing values
for the confounding variables to a separate category.
We did three sensitivity analyses: defining bispho-
sphonate exposure as two or more prescriptions;
restricting analyses to patients with complete data on
smoking,alcohol,andbodymassindex(completecase
analysis); and restricting data on bisphosphonate pre-
scription, smoking, and alcohol use to that recorded
more than one year before the index date. The results
of sensitivity analyses, including the complete case
analysis, suggested that use of a multiple imputation
method for dealing with missing data was not neces-
sary in this dataset and may in any case not be
appropriate, given the association between bispho-
sphonate use and the extent of missing data on poten-
tial confounding variables.
We also did analyses of the risk of cancer associated
with prescription of bisphosphonates within groups
defined by various factors that may be related to pre-
scription of bisphosphonates and to risk of gastro-
intestinal cancer. In addition to age at diagnosis, sex,
smoking status, alcohol drinking, and body mass
index, these included diagnosis of osteoporosis or
osteopenia within the observation period (yes or no);
diagnosisoffracture(anysite)recordedbeforethe first
bisphosphonate prescription (yes or no: analysis
restrictedtothosewithatleast 12months’observation
before the first bisphosphonate prescription); diagno-
sis of upper gastrointestinal disease (including oeso-
phagitis, gastro-oesophageal reflux disease, hiatus
hernia, oesophageal ulcers, Barrett’s oesophagus, gas-
tritis, duodenitis, peptic ulcers, and dyspepsia)
recorded before the first bisphosphonate prescription
(yes or no: analysis restricted to those with at least
12 months’ observation before the first bisphospho-
nate prescription); and prescription of non-steroidal
anti-inflammatory drugs (British National Formulary
section 10.1.1, including aspirin), corticosteroids (sec-
tions 6.3.2 and 10.1.2), or acid suppressant drugs
(includingH2receptoragonists,section1.3.1,andpro-
ton pump inhibitors, section 1.3.5) (yes or no; either at
any time during the observation period or before the
first bisphosphonate prescription).
We calculated estimates of the absolute risk of oeso-
phageal cancer in bisphosphonate users from the rela-
tive risks obtained here, applied to incidences of
oesophageal cancer typical for men and women aged
60-79 years in Europe and North America.
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RESULTS
The nested case-control study included 2954 men and
women with cancer of the oesophagus, 2018 with sto-
machcancer,10641withcolorectalcancer,andatotal
of 77750 matched controls. The mean observation
period was (by design) identical for cases and their
matched controls and was 7.5 years, on average.
Table 1 showsthe characteristics of cases and controls
forthethreecancersites.Overall,caseshadameanage
at diagnosis of 72 (SD 11) years, and 6744 (43%) were
female. Oesophageal and gastric cancer cases were
more likely to be smokers than were their matched
controls, whereas smoking status was similar for colo-
rectal cases and controls.
About 3% of the study population (415 cases and
2170 controls) had at least one prescription for an
oral bisphosphonate during the observation period.
Among the controls, those prescribed bisphospho-
nates were, as expected, older (44% (952/2170) of
those prescribed bisphosphonates were aged over 80,
compared with 26% (19419/75580) of those not pre-
scribedbisphosphonates)andmorelikelytobefemale
(80% (1732/2170) of those prescribed bisphospho-
nates compared with 42% (31885/75580) of those
not prescribed bisphosphonates). Differences in the
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matched controls, account for the small differences in
the proportion of controls for each cancer site pre-
scribed bisphosphonates. Before 2000, the most com-
monly prescribed bisphosphonate in both women and
men was etidronate. However, use of etidronate
declined markedly after the introduction of a weekly
formulation of alendronate in 2000, and by 2005 the
weekly formulations of alendronate and risedronate
accounted for almost all prescriptions.
Table 2showsdetailsofbisphosphonateprescribing
in cases and controls. Those with at least one prescrip-
tion for oral bisphosphonates had a significantly
increased risk of cancer of the oesophagus (adjusted
relative risk for one or more prescriptions v no such
prescription 1.30, 95% confidence interval 1.02 to
1.66;P=0.02)butnotofcancerofthestomach(relative
risk 0.87, 0.64 to 1.19) or colorectum (0.87, 0.77 to
1.00). The risk of oesophageal cancer was significantly
higher in people with 10 or more prescriptions for
bisphosphonate than in those with one to nine pre-
scriptions (mean number of prescriptions in cases
21.6 v 3.6; relative risks 1.93, 1.37 to 2.70 v 0.93, 0.66
to 1.31; P for heterogeneity by number of prescrip-
tions=0.002).Estimateddurationofuseofbisphospho-
nates was similarly related to risk of oesophageal
cancer: for use for less than one year, one to three
years and more than three years versus no prescrip-
tions, the relative risks were 0.98 (0.66 to 1.46), 1.12
(0.73 to 1.73), and 2.24 (1.47 to 3.43). The mean
duration of use in cases with more than three years of
use was 4.6 years. For the large majority of oesopha-
geal cancer cases and their controls with bisphospho-
nate prescriptions, the first prescription within the
follow-up period was at least 12 months after the start
of follow-up (75/90 (83%) cases; 290/345 (84%) con-
trols). In these patients, the relation between prescrip-
tionofbisphosphonateandriskofcancerwassimilarto
the overall findings (relative risk for any v no prescrip-
tion 1.28, 0.98 to 1.67; for ≥10 v no prescriptions 2.01,
1.37 to 2.94; for more than three years’ duration v no
prescription 2.48, 1.54 to 3.98). Most people pre-
scribed bisphosphonates had their last prescription
less than a year before their index date; the study had
insufficientpowertoassesstheseparateeffectsofdura-
tion of use and time since last use of bisphosphonates.
Table 2 shows relative risks adjusted for smoking,
alcohol, and body mass index. Unadjusted and
adjusted relative risks are given in web table A, which
showsthattheeffectofadjustmentforthesefactorswas
minimal. The bisphosphonate related risks were also
similar when we restricted analyses to the 1883 people
who died during the year after being diagnosed with
oesophageal cancer (relative risk for 1-9 v no prescrip-
tions0.87,0.56to1.34;for≥10vnoprescriptions2.29,
1.51 to 3.47; for more than three years of use v no pre-
scription 2.23, 1.26 to 3.95).
Riskofoesophagealcancerdidnotvarysignificantly
bytypeofbisphosphonateprescribed.Comparedwith
people with no prescriptions for bisphosphonates, the
Table 1 |Characteristics of gastrointestinal cancer cases and controls*. Values are numbers (percentages) unless stated
otherwise
Characteristics
Oesophageal cancer Gastric cancer Colorectal cancer
Cases
(n=2954)
Controls
(n=14 721)
Cases
(n=2018)
Controls
(n=10 007)
Cases
(n=10 641)
Controls
(n=53 022)
Mean years of observation 7.7 7.7 7.5 7.5 7.5 7.5
Female sex 1074 (36) 5345 (36) 770 (38) 3822 (38) 4900 (46) 24 450 (46)
Age (years) at index date:
40-59 489 (17) 2446 (17) 194 (10) 965 (10) 1764 (17) 8820 (17)
60-79 1706 (58) 8523 (58) 1163 (58) 5818 (58) 6162 (58) 30 807 (58)
≥80 759 (25) 3752 (25) 661 (33) 3224 (32) 2715 (26) 13 395 (25)
Smoking status:
Never 1208 (41) 7164 (49) 897 (44) 4937 (49) 5356 (50) 26 825 (51)
Past 680 (23) 2970 (20) 494 (25) 1958 (20) 2409 (23) 10 464 (20)
Current 729 (25) 2405 (16) 396 (20) 1544 (15) 1665 (16) 8123 (15)
Missing 337 (11) 2182 (15) 231 (11) 1568 (16) 1211 (11) 7610 (14)
Alcohol intake:
Non-drinker 466 (16) 2256 (15) 389 (19) 1664 (17) 1649 (15) 8277 (16)
Drinker 1893 (64) 8909 (61) 1206 (60) 5777 (58) 6777 (64) 31 958 (60)
Missing 595 (20) 3556 (24) 423 (21) 2556 (26) 2215 (21) 12 757 (24)
Body mass index (kg/m
2):
<25.0 811 (27) 3883 (26) 548 (27) 2631 (26) 2840 (27) 14 573 (27)
25.0-29.9 864 (29) 4459 (30) 567 (28) 2873 (29) 3203 (30) 15 694 (30)
≥30.0 403 (14) 1906 (13) 258 (13) 1203 (12) 1472 (14) 6808 (13)
Missing 876 (30) 4473 (30) 645 (32) 3300 (33) 3126 (29) 15 947 (30)
Prescribed oral
bisphosphonate
90 (3.0) 345 (2.3) 49 (2.4) 270 (2.7) 276 (2.6) 1555 (2.9)
*Five controls matched to each case by age at diagnosis of case (index date) to within 2 years, sex, general practice, and observation period in
General Practice Research Database.
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tion for etidronate (57 exposed cases), 1.28 (0.88 to
1.86) for any prescription for alendronate (37 exposed
cases), and 1.67 (0.94 to 2.95) for any prescription for
risedronate (17 exposed cases) (P for heterogeneity by
type=0.7). Numbers were too small to allow compari-
sonbetweendailyandweeklypreparationsofalendro-
nate or risedronate.
Bisphosphonate associated risk also did not vary
materially between groups of patients categorised by
age, sex, smoking status, alcohol intake, or body mass
index; by diagnosis of osteoporosis/osteopenia; or by
diagnosis of fracture or of upper gastrointestinal dis-
ease before prescription of bisphosphonate (figure).
Theriskwasalsosimilarwithingroupsdefinedbypre-
scription of acid suppressant drugs, non-steroidal anti-
inflammatory drugs, or corticosteroids, either at any
time during the observation period (as shown in the
figure) or before the first bisphosphonate prescription
(data not shown). We found no material differences
between the results reported here and those from the
threesensitivityanalysesdescribedintheMethodssec-
tion (table 3). For the complete case analysis, unad-
justed and adjusted relative risks were 1.08 (0.70 to
1.67) and 1.05 (0.68 to1.63) for one to nine versus no
prescriptions, and 1.99 (1.32 to 3.01) and 1.88 (1.24 to
2.86) for 10 or more versus no prescriptions.
Information on histological type was available for
only 20% (593/2954) of the oesophageal cancers.
When we used these data, the adjusted relative risks
for one or more bisphosphonate prescriptions versus
no prescription were 2.02 (1.02 to 4.01) among 437
cases of adenocarcinoma and 2183 matched controls
and 0.83 (0.36 to 1.93) among 156 cases of squamous
cellcarcinomaand776matchedcontrols(Pforhetero-
geneity by tumour histology=0.1).
DISCUSSION
In this large nested case-control study within a UK
cohort with prospectively recorded information on
prescribing of bisphosphonates, we found a signifi-
cantly increased risk of oesophageal cancer in people
with previous prescriptions for oral bisphosphonates.
The increased risk was largely restricted to those with
10 or more prescriptions and with prescriptions span-
ning many years. For example, prescribing of bispho-
sphonates over a period of about five years was
associated with a doubling of the risk of oesophageal
cancer. The association did not vary materially within
subgroupsdefinedbyage,sex,smokingstatus,alcohol
drinking, or body mass index; diagnosis of osteoporo-
sis, previous fracture, or previous upper gastro-
intestinal disease; or prescription of non-steroidal
anti-inflammatory drugs, corticosteroids, or acid sup-
pressant drugs. In contrast to the findings for oesopha-
geal cancer, risks for cancer of the stomach and cancer
ofthecolorectumwerenotsignificantlyincreasedafter
prescription of bisphosphonates.
Strengths and limitations of study
This study has the advantage of large size, with nearly
3000 cases of oesophageal cancer, and of reliable and
complete prospectively recorded data on all prescrip-
tions. Participants with oesophageal cancer and their
matched controls were observed for an average of
almost eight years, and we had enough cases and con-
trols with 10 or more bisphosphonate prescriptions to
allow analysis by number of prescriptions and esti-
mated duration of use. Data were available for most
of the study participants on the main factors that have
been associated with risk of oesophageal cancer,
including smoking, alcohol intake, and body mass
index. Adjustment for these minimised the scope for
Table 2 |Relative risks (RRs) and 95% confidence intervals (CIs) for incident gastrointestinal cancer at specified sites, in relation to prescription of oral
bisphosphonates
Oral
bisphosphonates
Oesophagus Stomach Colorectum
Prescriptions*
Cases/
controls
RR†
(95% CI) Prescriptions*
Cases/
controls
RR†
(95% CI) Prescriptions*
Cases/
controls
RR†
(95% CI)
Not prescribed NA 2864/14 376 1.00 NA 1969/9737 1.00 NA 10365/51467 1.00
Prescribed 13.6/2.4 90/345 1.30
(1.02to1.66)
8.9/1.4 49/270 0.87
(0.64to1.19)
11.0/1.9 276/1555 0.87
(0.77 to 1.00)
No of prescriptions:
1-9 3.6/1.0 40/214 0.93
(0.66to1.31)
3.0/0.4 28/160 0.84
(0.56to1.27)
3.8/0.8 164/880 0.92
(0.77 to 1.09)
≥10 21.6/3.5 50/131 1.93
(1.37to2.70)
16.6/2.8 21/110 0.91 (0.57 to
1.47)
21.6/3.7 112/675 0.82
(0.67 to 1.00)
Estimated duration
of use‡:
≤1 year 4.9/0.3 31/155 0.98
(0.66to1.46)
3.5/0.3 26/123 1.03
(0.67to1.59)
3.3/0.3 120/647 0.91
(0.75 to 1.11)
1-3 years 13.0/2.0 26/114 1.12
(0.73to1.73)
11.9/1.8 16/86 0.89
(0.52to1.53)
11.6/1.8 91/544 0.83
(0.66 to 1.04)
≥3 years 22.2/4.6 33/76 2.24
(1.47to3.43)
21.6/4.9 7/61 0.54
(0.24to1.18)
24.3/5.1 65/364 0.88
(0.67 to 1.15)
NA=not applicable.
*Prescriptions of bisphosphonates in cases; reported as mean number/mean years.
†All relative risks adjusted for smoking status, alcohol intake, and body mass index.
‡Time between first and last prescription.
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lyses that excluded participants with missing data on
any of the adjustment variables gave results virtually
identical to those in the overall analysis. The General
Practice Research Database is based on a representa-
tive sample (about 7%) of the UK population,
3 and the
results of this study, which includes men and women
acrossawideagerangeandwithvaryingbackgrounds,
should be generalisable to other populations.
LimitationsofthestudyincludethefactthattheGen-
eral Practice Research Database records prescriptions
issuedbutnotwhetherthe drugswereusedorwhether
the instructions on taking these drugs, designed to
minimise the risk of oesophageal irritation, were
followed.
7 Not everyone prescribed bisphosphonates
will use them,
8 but this is less likely to be true among
peoplewithmanyprescriptions—forexample,with10
or more bisphosphonate prescriptions—or with pre-
scriptions over many years. Furthermore, low compli-
ance would result in underestimation of the risk
associated with bisphosphonate use and should not
producespuriousassociations.Wehadnoinformation
on bisphosphonate prescriptions before a patient’s
entryintothedatabase,butbisphosphonateassociated
risks were similar when analyses were restricted to
those with their first bisphosphonate prescription at
leasta yearafterthe startof theirperiodofobservation
in the General Practice Research Database.
Data in the General Practice Research Database on
incidence of cancer by site are reliable,
4 but informa-
tion on tumour histology is incomplete. Oesophageal
squamouscellcarcinomasandadenocarcinomasdiffer
withregardtosomeriskfactors,
9includingtheeffectof
alcohol and body mass index.
1011 Although we found
no significant difference in bisphosphonate associated
relativeriskbyhistologicaltype,ouranalyseswerelim-
ited by small numbers of exposed cases with relevant
data.
We did our analyses to test the specific hypothesis
thatoralbisphosphonatesincreasetheriskofoesopha-
gealcancer.Weincludedgastricandcolorectalcancers
in our analyses to compare the findings for these two
other gastrointestinal cancers (for which no prior
hypothesis existed) with those for oesophageal cancer.
We used identical criteria to select cases and controls
for the three cancers and did identical analyses for
each.Thespecificityoftheassociationforoesophageal
cancer argues against methodological problems in the
selection of cases and controls or in the analysis. As
bisphosphonate users may be more likely to be inves-
tigated for upper gastrointestinal tract symptoms and
thus be diagnosedashaving early oesophagealcancer,
wedidananalysisrestrictedtopeoplewhodiedwithin
a year of diagnosis of oesophageal cancer (as they are
less likely to have had an early diagnosis), and the
results were similar to those of the main analysis. Nor
istheassociationlikelytobeduetoahigherunderlying
risk of oesophageal cancer in people prescribed
bisphosphonates; if anything, symptoms of oesopha-
geal disease might be expected to result in the avoid-
ance of bisphosphonates (and thus to an
underestimation of risk). The effect of previous gastro-
intestinal disease on bisphosphonate prescribing is,
however, probably more complex than this.
12 All the
cases in thisstudy were diagnosedseveralyears before
the publication of a possible link between bisphospho-
nates and oesophageal cancer, so the association can-
not tobe dueto selective surveillanceafterpublication
of recent reports.
We found similar risks for oesophageal cancer asso-
ciated with prescription of bisphosphonates in people
with and without a recorded diagnosis of osteoporosis
and in those with and without a fracture recorded
before prescription of bisphosphonates. The risk also
didnotvarysignificantlywithingroupsdefinedbypre-
vious upper gastrointestinal disease or by prescription
of other drugs for which use may be related to risk of
osteoporosis or gastrointestinal disease, including can-
cer, and to prescription of, as well as side effects from,
oral bisphosphonates. We cannot rule out the possibi-
lity that the associations observed reflect other,
unknown, factors that are linked to prolonged use of
bisphosphonatesandthatalsoincreasetheriskofoeso-
phageal cancer.
Comparison with other studies
In early 2009 the possibility of a link withoesophageal
cancer was raised by a report of 54 adverse reaction
case reports received by the US Food and Drug
Administration from the United States, Europe, and
Japan.
2 A causal association is plausible: upper gastro-
intestinal side effects, including oesophagitis, are clini-
cally recognised with oral bisphosphonates,
1 and
inflammation of the oesophagus is a risk factor for
both squamous cell carcinoma and adenocarcinoma
of the oesophagus. Two brief reports were published
Table 3 |Sensitivity analyses comparing relative risks for oesophageal cancer in relation to prescription of oral bisphosphonates, using varying criteria for
definition of exposure and inclusion of adjustment variables
Sensitivity analyses
No of exposed cases
of oesophageal cancer
Relative risk* (95% CI)
1-1-9 v 0 prescriptions
Relative risk* (95% CI)
≥10 v 0 prescriptions
Main analysis: bisphosphonate exposure defined as ≥1 prescription within observation
period; missing data on adjustment variables assigned to separate category
90 0.93 (0.66 to 1.31) 1.93 (1.37 to 2.70)
Bisphosphonate exposure defined as ≥2 prescriptions 80 0.93 (0.63 to 1.39) 1.93 (1.37 to 2.70)
Restricted to those with full information on adjustment variables 68 1.05 (0.68 to 1.63) 1.88 (1.24 to 2.86)
All exposure and adjustment data recorded at least 12 months before index date, and
restricted to those with full information on adjustment variables
52 1.09 (0.67 to 1.79) 2.00 (1.23 to 3.27)
*Adjusted for smoking status, alcohol intake, and body mass index.
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lication. Solomon and colleagues reported no signifi-
cant difference in incidences of oesophageal cancer
betweenpeopleinaUSMedicarehealthplandatabase
prescribedbisphosphonatesforosteoporosisandthose
prescribedotherdrugsforosteoporosis(incidencerate
ratio 0.55, 95% confidence interval 0.06 to 4.72) or
betweenbisphosphonateusersandthegeneralpopula-
tion (incidence rate ratio 1.12, 0.26 to 4.84).
13 The
value of this study is difficult to assess, as the publica-
tion provided no information on numbers of exposed
or unexposed cases or on details of the analysis. Abra-
hamsen and colleagues examined risk of incident
upper gastrointestinal cancer in people with previous
fracture identified from national registers in
Denmark.
14 They found a reduced risk of oesophageal
cancer in people with prescriptions for oral bispho-
sphonates,comparedwiththosewithnosuchprescrip-
tions,overa meanof2.8years’follow-up(hazardratio
0.35,95%confidenceinterval0.14to0.85,basedon37
cases). No data were available on long term exposure
to bisphosphonates.
14 Similarly, no significant associa-
tionbetweenprescriptionoforal bisphosphonatesand
incidence of oesophageal adenocarcinoma was found
in a recent US nested case-control study of patients
with Barrett’s oesophagus (relative risk 0.92, 95% con-
fidence interval 0.21 to 4.15), but this study included
only two exposed cases and lacked information on
potential confounders.
15
Between acceptance and publication of this paper,
another report on oral bisphosphonates and risk of
oesophageal cancer, also using data from the General
Practice Research Database, was published.
16
Although that study, by Cardwell et al, and ours used
the same database, with prospectively recorded infor-
mation on prescribing of bisphosphonates, the obser-
vation time is nearly twice as long in our analysis as in
Cardwell et al’s analysis (on average 7.7 v 4.5 years).
Ourstudythushadthepotentialtoincludepeoplewith
longer durations of bisphosphonate use and also had
greater statistical power, with five matched controls
per case compared withequal numbersin the exposed
and comparison groups in Cardwell et al’s study.
In our study, the excess risk of oesophageal cancer
was largely restricted to people with 10 or more
bisphosphonate prescriptions and to those with pre-
scriptions over more than three years. In Cardwell et
al’sreport,peoplewithgreaterthan1095defineddaily
doses of bisphosphonates, which is broadlyequivalent
to more than three years of use, had an incidence of
oesophageal cancer of 6.6 per 10000 person years,
based on only 15 cases; those with fewer defined
daily doses had an incidence of 4.5 per 10000 person
years, giving an unadjusted relative risk for more than
1095 versus fewer defined daily doses of bisphospho-
nates of 1.46 (95% confidence interval 0.78 to 2.60).
Cardwell et al report an unadjusted relative risk of
1.08 (0.52 to 2.23) in bisphosphonate users with more
than 1095 defined daily doses compared with their
matched controls. For both of these estimates the con-
fidence intervals are wide, however, and the relative
2864/50
1220/9
1644/41
1856/12
1008/38
1366/22
1166/26
1879/33
406/8
764/24
1241/17
2864/13
2864/27
44/31
2820/19
2864/8
2864/32
1796/41
1068/9
1894/41
970/9
593/30
2271/20
1.93 (1.37 to 2.70)
3.14 (1.32 to 7.46)
1.77 1.22 to 2.56)
1.57 (0.81 to 3.04)
2.08 (1.40 to 3.08)
1.55 (0.94 to 2.58)
2.22 (1.40 to 3.52)
2.08 (1.36 to 3.16)
1.18 (0.54 to 2.60)
2.27 (1.38 to 3.74)
1.72 (0.98 to 3.03)
3.07 (1.53 to 6.21)
1.73 (1.10 to 2.72)
1.75 (1.01 to 3.01)
1.64 (0.96 to 2.78)
1.55 (0.69 to 3.47)
2.16 (1.41 to 3.32)
1.81 (1.25 to 2.62)
2.53 (1.12 to 5.69)
1.30 (0.87 to 1.95)
1.99 (0.96 to 4.13)
1.91 (1.22 to 2.98)
1.66 (0.99 to 2.78)
012345
Category Relative risk
(95% CI)
Relative risk
(95% CI)
Cases (0 prescriptions/
≥10 prescriptions)
All women
Age at index date
  40-69 years
  ≥70 years
P for heterogeneity=0.2
Sex
  Men
  Women
P for heterogeneity=0.5
Smoker
  Yes
  No
P for heterogeneity=0.3
Alcohol drinker
  Yes
  No
P for heterogeneity=0.2
Body mass index
  <25
  ≥25
P for heterogeneity=0.5
Previous upper gastrointestinal disease diagnosis*
  Yes
  No
P for heterogeneity=0.2
Osteoporosis diagnosis
  Yes
  No
P for heterogeneity=0.9
Previous fracture diagnosis*
  Yes
  No
P for heterogeneity=0.5
Prescribed non-steroidal anti-inflammatory drug
  Yes
  No
P for heterogeneity=0.5
Prescribed acid suppressant drug
  Yes
  No
P for heterogeneity=0.3
Prescribed corticosteroids
  Yes
  No
P for heterogeneity=0.8
Relative risks of incident oesophageal cancer in people with ≥10 prescriptions for oral
bisphosphonates, compared with those with no prescriptions, by various factors. Relative risks
adjusted for smoking status, alcohol intake, and body mass index, as appropriate. *Diagnosis
before prescription of bisphosphonates: analyses restricted to those with ≥12 months’
observation before first bisphosphonate prescription
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stable estimate of 2.24 (1.47 to 3.43) for more than
three years versus no prescriptions. Thus, as would
be expected, when broadly equivalent exposures are
compared, the results from our analyses and those of
Cardwell et al do not differ significantly.
Conclusions and policy implications
Oral bisphosphonates are the recommended first line
treatment for primary and secondary prevention of
osteoporotic fracture in both men and women in Eur-
ope and in North America.
17-19 Osteoporosis is com-
mon, especially among postmenopausal women, and
is associated with considerable morbidity and mortal-
ity.Prescribingofbisphosphonatesisincreasing;inthe
UK, for example, about 3% of women aged over 70
received a prescription for oral bisphosphonates in
2000, rising to 10% in 2005.
20 Evidence from rando-
mised controlled trials suggests that the oral bispho-
sphonates most commonly prescribed in this study
(alendronate, etidronate, and risedronate) reduce the
risk of fracture in postmenopausal women at high risk
of fracture,
21-23 but little evidence for such a benefit
exists in women at low risk of fracture, in men,
24 or
among those with more than four years’ use. No ran-
domised trial of bisphosphonates was large enough or
continuedforlongenoughtohavedetectedadoubling
of risk for oesophageal cancer. Concerns have been
raised about other adverse effects of long term use of
oral bisphosphonates; these include osteonecrosis of
the jaw,severe musculoskeletal pain,atrial fibrillation,
and bone micro-damage caused by long term suppres-
sion of bone turnover, leading to increased risk of aty-
pical fracture.
25 Although bisphosphonate use has
been reported to be associated with a reduced risk of
breast cancer,
26 this association is unlikely to be causal
as risk of breast cancer is known to be reduced in
women with osteoporosis.
27
Oesophageal cancer is not common in Western
countries, but it has a high morbidity and is often
fatal. On the basis of incidences for Europe and
North America published by the World Health Orga-
nization in 2007,
6 a doubling of risk of oesophageal
cancer associated with about five years’ use of oral
bisphosphonates would mean an estimated overall
increase in incidence of oesophageal cancer in people
aged60-79yearsfrom1caseper1000populationover
fiveyearsinbothsexescombined(inwomen0.5andin
men1.5per1000)innon-usersto2casesper1000over
five years (in women 1 case and in men 3 cases per
1000) in users.
If confirmed, an association between use of oral
bisphosphonates and risk of oesophageal cancer
would add to our knowledge of the risks and benefits
of use of oral bisphosphonates. Treatment and preven-
tion of osteoporotic fracture is a subject of increasing
public health importance with large scale clinical and
economic implications. Further research is warranted
to confirm or refute our findings and in particular to
examine the associations between use of different
types and formulations of bisphosphonates and risk of
the different histological types of oesophageal cancer.
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